dan 2163 has been researched along with Mood Disorders in 2 studies
Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hopkins, SC | 1 |
| Wilkinson, S | 1 |
| Corriveau, TJ | 1 |
| Nishikawa, H | 1 |
| Nakamichi, K | 1 |
| Loebel, A | 1 |
| Koblan, KS | 1 |
| Silvestre, FJ | 1 |
| Silvestre-Rangil, J | 1 |
| López-Jornet, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)[NCT03543410] | Phase 2 | 344 participants (Actual) | Interventional | 2018-06-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical Global Impressions - Severity: Bipolar Version (CGI-BP-S) score (depression) is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill subjects. A higher score is associated with greater illness severity. (NCT03543410)
Timeframe: 6 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| SEP-4199 200 mg | -2.020 |
| SEP-4199 400 mg | -1.958 |
| Placebo | -1.739 |
MADRS is a clinician-rated assessment of the subject's level of depression. The measure contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal thoughts, each ranging from 0 to 6. The MADRS total score ranges from 0 to 60, with higher scores indicating increased depressive symptoms (NCT03543410)
Timeframe: 6 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| SEP-4199 200 mg | -19.485 |
| SEP-4199 400 mg | -19.324 |
| Placebo | -16.196 |
1 review available for dan 2163 and Mood Disorders
| Article | Year |
|---|---|
Burning mouth syndrome: a review and update.
Topics: Adult; Age Distribution; Aged; Algorithms; Amisulpride; Antidepressive Agents; Burning Mouth Syndrom | 2015 |
1 trial available for dan 2163 and Mood Disorders
| Article | Year |
|---|---|
Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders.
Topics: Adult; Amisulpride; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dopamine | 2021 |